A Phase I Study of GNKG168 in Pediatric Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (IND#113600)
Latest Information Update: 14 Jan 2020
At a glance
- Drugs GNKG 168 (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 29 May 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Jan 2013 New trial record